Brief: Carsgen Therapeutics Sys US FDA Granted IND Clearance For CT071
04/12/2023 01:04
Dec 4 (Reuters) - CARsgen Therapeutics Holdings Ltd
2171.HK :
* US FDA GRANTED IND CLEARANCE FOR CT071
* IND CLEARANC FOR CT071 FOR TREATMENT OF
RELAPSED/REFRACTORY
MULTIPLE MYELOMA OR RELAPSED/REFRACTORY PRIMARY PLASMA CELL
LEUKEMIA
Further company coverage: 2171.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer